Introduction
Ochroconis spp. are dematiaceous fungi and cause phaeohyphomycosis [1 -11] . Members of the genus have been isolated worldwide from soil, thermal springs, and decaying vegetation [1,2,4 -6,11 -15] . They have also been identifi ed in chicken litter and the effl uents of thermal nuclear reactors [1,4 -6,11,14,16 -20] . Although Ochroconis spp. have traditionally been regarded as a cause of brain abscesses and encephalitis in birds and other animals subcutaneous abscesses [9] . In addition, black deposits were found around the catheter lumen of a cardiac transplant patient on continuous ambulatory peritoneal dialysis [15] . However, more commonly, infections in these two groups have presented as a combination of both pulmonary and extra-pulmonary disease, particularly involving the brain, spleen, skin, and other organ sites. Although a number of patients with extra-pulmonary disease have survived [2, 23, 28] , it is more frequently associated with poor clinical outcomes [6, 7, 12, 17, 18, 25, 26] .
The remainder, and minority, of cases of Ochroconis infections have been in either immunocompetent patients or in immunocompromised individuals who have neither undergone transplantation nor have a history of being treated for hematologic malignancy (Table 1) . Odell et al . described a surviving wood pulp worker with pulmonary nodules likely due to occupational exposure to Ochroconis [4] . Hollingsworth et al . reported a surviving immunocompetent patient with progressively worsening shortness of breath of 3 months duration, multiple pulmonary nodules, and bronchoalveolar lavage (BAL) samples that yielded both Ochroconis and Aspergillus versicolor [10] . Other reports include an HIV-infected patient with dissemination of the infection to the lungs, joints, and brain [3] ; a patient with failure to thrive from whom Mycobacterium avium complex (MAC) and Ochroconis spp. were recovered from BAL samples [5] ; and a patient with pemphigus and an isolated pulmonary Ochroconis infection [27] .
A variety of treatment regimens have been both attempted and advocated, including voriconazole, itraconazole, posaconazole, and amphotericin B [1, 6, 8, 11, 14, 15, 23, 26, 28] . A combination of surgery and systemic treatment with amphotericin B or itraconazole has been recommended for systemic phaeohyphomycoses [23] . However, defi ned treatment guidelines have not as of yet been established. We present a case of O. gallopava infection in a patient with a history of chronic granulomatous disease (CGD) and chronic Aspergillus infections. The extent of disease in this case was limited to the lung.
This case underscores some of the potential complexities associated with treating such infections, including the use and interpretation of antibiotic susceptibility data for Ochroconis , and the factors dictating antibiotic selection and management. The paucity of Ochroconis infections in humans has two potential consequences. First, clinicians may fail to consider it in their differential diagnosis. Second, the microbiology lab may mistakenly dismiss the organism as a contaminant, rather than acknowledging it as a true pathogen [6, 7, 29] . Because of the high mortality rate reported caused by this organism (estimated at 50%), proper recognition and treatment of Ochroconis infections are paramount [1, 23, 26] . Therefore, the microbiology of Ochroconis spp. and the various treatment modalities which have been employed will be discussed.
Case report
The patient is a 34-year-old male with a history since the age of two of chronic granulomatous disease, who experienced an episode of staphylococcal pneumonia involving the right lower lung at the same age. In 1991 (age 14), he developed pneumonia in his right upper lobe that required resection. Cultures of material from this procedure grew Aspergillus fumigatus and A. niger . He was treated with and discharged on amphotericin B (60 mg IV in 600 cc of 5% dextrose in water (D5W) run over 4 hours three times weekly), subcutaneous gamma interferon (70 μ g subcutaneously three times weekly), 5-fl uorocytosine (1 g PO daily), and prophylaxis with trimethoprimsulfamethoxazole (TMP-SMX; one double-strength capsule PO twice daily). Five years later, he was re-admitted to the hospital for Francisella philomiragia sepsis treated with ciprofl oxacin. The following year, he underwent a right lower lobe wedge resection. In 1998 (age 21), he experienced a second episode of invasive pulmonary aspergillosis (IPA) infection, which was treated with right upper lobectomy, as well as amphotericin B (dosing unclear), itraconazole (200 mg PO twice daily, for a total of 400 mg/day), and gamma interferon (75 μ g subcutaneously three times weekly). He continued prophylaxis with TMP-SMX.
In February 2011, he presented with a productive cough and rhinorrhea, a white blood cell count of 8670/cu mm, and an absolute neutrophil count of 6440/cu mm. He was empirically treated for pneumonia with azithromycin. At this time, he was already on itraconazole 400 mg PO daily as secondary therapy of his IPA and one double-strength capsule of TMP-SMX PO twice daily. A CT scan, approximately fi ve weeks later, showed continued extensive disease in the right lung and a small left upper lobe infi ltrate. A BAL was performed, and cultures inoculated with a portion of the BAL yielded Ochroconis spp. The patient ' s antifungal regimen was then switched from itraconazole to voriconazole (200 mg PO twice daily). Five weeks after voriconazole was initiated, the patient continued to have pulmonary symptoms, and underwent CT scan which revealed volume loss and a large cavitary lesion in the right lung with complete consolidation of the remaining bronchi. He was readmitted for a completion right-side pneumonectomy. At the time of admission, his white blood cell count was 6610/cu mm, and his absolute neutrophil count was 4770/cu mm. His pneumonectomy specimen was submitted to surgical pathology for gross and histologic review, and sent to the microbiology lab for evaluation. Gross pathology of the right upper lobe revealed pleural adhesions, consolidation with some areas of degenerative cystic change, but otherwise no discrete masses (data not included). On histopathologic review of H&E stain samples (Fig. 1A) , there was evidence of extensive acute bronchopneumonia, characterized by clusters of neutrophils in the airspaces. Organization was also present, demonstrated by infl ammatory cells and myofi broblasts within a myxoid matrix. Necrotizing granulomas were abundant. Fungal organisms were not visible on the H&E stain material. A Grocott methenamine silver (GMS) stain (Fig. 1B) highlighted light fi lamentous fungal structures, although the presence or absence of septations was diffi cult to ascertain.
The lung tissue submitted to the microbiology laboratory yielded, as with the BAL sample from February 2011, a fungus consistent with Ochroconis spp. which was subsequently identifi ed as O. gallopava (see below).
The organism was also sent for antibiotic susceptibility testing.
Two weeks following the patient ' s lung resection, his voriconazole dose was increased from 200 -250 mg PO twice daily, with a target serum level of 4 -5 μ g/ml. Hepatic function was concomitantly monitored. As he was below his target voriconazole levels, his dose was increased shortly thereafter to 300 mg PO twice daily. His voriconazole levels increased only slightly, but his transaminases markedly increased. Results of antibiotic susceptibility studies of the fungus revealed that its minimal inhibitory concentration (MIC) to voriconazole was 2 μ g/ml, while that of posaconazole was 0.125 μ g/ml. The high MIC for voriconazole in the setting of worsening liver function tests prompted a switch, at six weeks following the resection, to posaconazole, titrated to a fi nal dose of 400 mg PO three times daily based on serum levels. At eight weeks postresection, he developed acute sinusitis for which he was treated with levofl oxacin. He was otherwise doing well postoperatively.
Morphological identifi cation
Colonies of the fungus on Sabouraud dextrose agar at 25 ° C were brownish-black on the surface and reverse, with a dark reddish diffusible pigment and a woolly texture ( Fig. 2A) . Examining a lactophenol cotton blue (LPCB) stained mount from the potato fl akes agar (PFA) slide culture revealed conidiophores that were slender and pointed, bearing 1 -2 conidia at the tip of the denticles; these conidia were palebrown, clavate, two-celled, and smooth walled (Fig. 2B) . The fungus did not grow on Mycosel agar after either seven and 12 days of incubation clearly suggesting that it was inhibited by cycloheximide. Temperature studies revealed that the isolate was capable of growing at 25 ° C (positive control), 37 ° C, and 45 ° C on brain heart infusion (BHI) agar and the urease test was positive at day 7. Based on these features, the organism was identifi ed as O. gallopava .
Molecular identifi cation
DNA sequencing identifi cation was also performed on this isolate. After DNA extraction using Zymo Research ZR Fungal DNA Kit (Zymo Research, Orange, CA, USA), the internal transcribed spacer (ITS) region (ITS1 -5.8S-ITS2) and the D1/D2 region of 28S ribosomal DNA were amplifi ed and sequenced. PCR reactions were conducted using the TAQ polymerase and the following amplifi cation conditions for ITS (ITS 1 primer: 5 ¢ -TCC GTA GGT GAA CCT GCG G-3 ¢ , ITS 4 primer: 5¢ -TCC TCC GCT TAT TGA TAT GC-3 ¢ ), hold at 95 ° C for 5 min, followed by 30 cycles of the following; 95 ° C for 30 sec, 55 ° C for 1 min, 72 ° C for 1 min, and fi nal extension at 72 ° C for 6 min. The D1/D2 region of ribosomal DNA was also amplifi ed and sequenced using PCR reactions with TAQ polymerase and the following conditions for D1/D2 (NL-1 primer: 5¢ -GCA TAT CAA TAA GCG GAG GAA AAG-3¢ , NL-4 primer: 5 ¢ -GGT CCG TGT TTC AAG ACG G-3 ¢ , hold at 94 ° C for 2 min, followed by 30 cycles of the following: 94 ° C for 15 sec, 55 ° C for 30 sec, 68 ° C for 2 min, and fi nal extension at 68 ° C for 5 min. PCR amplicons were sequenced using an ABI Prism 3100 genetic analyzer (Applied Biosystems, Foster City, CA, USA). The ITS and D1/D2 sequences were used to perform a BLAST search using of the NCBI database (http://blast.ncbi.nlm.nih.hov/Blast.cgi), and the SmartGene (SmartGene Inc., Raleigh, NC, USA) software and library. The sequence results from the ITS region and D1/D2 regions matched 100% and 99.47%, respectively, with O. gallopava in both the SmartGene library and NCBI database.
Antifungal susceptibility testing
Antifungal susceptibilities were performed using broth microdilution by the Fungus Testing Laboratory at the University of Texas Health Science Center in San Antonio, Texas. Minimal inhibitory concentration (MIC) results in μ g/ml are shown in Table 2 . The MIC studies were performed once (acceptable error range of Ϯ 1 doubling dilution).
Discussion
Ochroconis (formerly known as Dactylaria ) is a recognized dematiaceous fungal genus, encompassing several species including O. constricta , O. gallopava and O. humicola [1 -11,25] . Although the organism has a worldwide distribution, a number of cases of human infections have been described in the southeastern USA [7, 11, 18] . Its exact mode of transmission is unclear, but it is hypothesized that Ochroconis might be acquired from direct trauma or via inhalation of conidia [6,30 -32] .
The colonies of all Ochroconis species are brown-olive, and have a velvety texture. Microscopically, they are characterized by brown septate hyphae, brown unbranched conidiophores with apical denticles arranged sympodially, and brown club-shaped conidia with 1 -3 transverse septations. O. gallopava bears two-celled conidia that are constricted at the septum, and are described as being clavate with an apical cell that is wider than the basal cell. It cannot grow on Mycosel agar, but grows rapidly on other media at 37 ° C, and is gelatin liquefaction-negative. Additionally, it produces a distinctive reddish difusable pigment on Sabouraud dextrose agar ( Fig. 2A) [33 -35] . It is important to recognize that many dematiaceous fungi should not be considered as representing contaminants and discarded in being processed in the clinical laboratory as they may be the etiologic agents of infections [6, 7, 29] .
Ochroconis frequently involves the lungs, either causing cavitary or non-cavitary lung lesions, and has a predilection for the upper and mid lung fi elds. Our patient, as with several others with Ochroconis infection, had isolated pulmonary involvement [1, 4, 5, 8, 10, 11, 24, 27] . Disease limited to the lungs has typically been associated with good clinical outcomes (our study included), when such data is provided in case reports [4, 8, 10, 11, 24, 27] . Ochroconis gallopava has a particular tropism for the central nervous system, presenting as cerebral abscesses [3, 7, 11, 12, 23, 25, 25, 26, 28] . Infections may commonly involve multiple organ sites, including the thyroid [12] , spleen [26] , skin [2] , liver [18] , kidney [18] , and joints [3, 23] . In a literature review of 12 cases, Shoham et al . reported multi-organ and brain involvement in 60% and 50% of cases, respectively, survival of 100% if the infection involved the lung, with or without another organ, and survival of 33% with more extensive disease [11] . Several studies suggest that posaconazole and itraconazole may be optimal therapies for Ochroconis infection, followed by amphotericin B and voriconazole, and that 5-fl uorocytosine and fl uconazole are the least effective [1, 6, 8, 11, 14, 15, 23, 26, 28] (including our study; Table 2 ). However, it should be noted that there are currently no established guidelines for treatment regimens or duration. Our patient did not clinically respond to itraconazole taken for IPA, and developed Ochroconis infection. Since itraconazole serum or plasma levels were not measured in our patient, it is not clear if this lack of response was due to an insuffi cient does to prevent Ochroconis infection. Of note, the MIC for itraconazole was unusually high compared to those previously reported (MIC ϭ 0.5 μ g/ml; Table 1 , [1, 6, 11, 14, 15, 23, 26, 28] ). A dose of voriconazole of 300 mg PO twice daily failed to reach target levels of 2 -5 μ g /ml and caused an elevation in transaminases. The relatively high MIC of voriconazole (MIC 2 μ g/ml, Table  1 ) precluded titration to a higher dose and an increase may have precipitated a greater rise in his liver function tests. As with itraconazole, the MIC for voriconazole was higher in comparison to that obtained described in prior reports (Table 2, [1, 11, 15, 26] ). Although our patient did have long-term exposures to itraconazole and voriconazole and while we found elevated MIC values of these two drugs compared to those in prior reports in the literature, it is hard to know if the long-term exposure played any role in elevating the MICs since they were not measured pre-and post-exposure.
Antifungal susceptibility testing can be helpful in guiding clinical management of patients with fungal infections, as in this case. However, one limitation is that there are no clinically defi ned breakpoints for fi lamentous fungi. The lack of interpretative breakpoints makes the MIC diffi cult to interpret [36] . The importance of variable azole MICs found with Ochroconis species remains unclear. But, clinically signifi cant azole resistance has been increasingly important within other fi lamentous fungi, such as Aspergillus species. Breakthrough infections with azole-resistant Aspergillus strains in patients on long-term itraconazole prophylaxis have been reported [37 -39] . It is our contention that -by a mechanism analogous to that seen in Aspergillus spp. -long-term therapy with itraconazole and voriconazole may have encouraged development of microbiologic resistance to these azoles and high MICs, resulting in a breakthrough Ochroconis infection.
Our case highlights the intricacies associated with treatment of Ochroconis infection, including antibiotic susceptibility testing, as well as antibiotic selection and management. Although infection with Ochroconis spp. is exceptional, it is its rarity which warrants an awareness of this organism and understanding of its microbiology to better protect patients from this potentially aggressive fungal pathogen.
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